Chugai Pharmaceutical (OTCMKTS:CHGCY) Stock Price Down 10.2% - Here's Why

Key Points

• Chugai Pharmaceutical's stock price plummeted by 10.2%, trading as low as $22.44 before closing at $22.50.
• The company experienced a significant decline in trading volume, with only 29,199 shares exchanged compared to an average of 203,705.
• Chugai reported $0.20 earnings per share and $2.01 billion in revenue for the last quarter, showcasing a net margin of 33.08%.

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report)'s stock price fell 10.2% on Thursday . The company traded as low as $22.44 and last traded at $22.50. 29,199 shares changed hands during trading, a decline of 86% from the average session volume of 203,705 shares. The stock had previously closed at $25.06.

Chugai Pharmaceutical Price Performance

The company has a market capitalization of $65.67 billion, a PE ratio of 25.26 and a beta of 0.65. The firm has a 50-day moving average of $24.95 and a 200 day moving average of $24.67.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The company reported $0.20 earnings per share (EPS) for the quarter. The firm had revenue of $2.01 billion for the quarter. Chugai Pharmaceutical had a net margin of 33.08% and a return on equity of 20.80%. Equities analysts expect that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.